Long-term Effects on Muscle Recovery

What Long-Term Means Here

Most people who use peptides for recovery do it in courses: a few weeks around an injury, or a few months during a hard training block. Over a career, those courses can add up to years of exposure. This page covers what is known about repeated or extended use. For how each peptide is supposed to work in the short term, start with our overview of peptides and muscle recovery.

Long-term human data exist for one class, the growth hormone (GH) secretagogues. For the peptides lifters use most for injuries, BPC-157 and TB-500, there are none. Forum guides often claim that recovery peptides improve tissue quality over months or cut injury rates over years. We found no study that measured either outcome.

How Long the Studies Ran

Growth Hormone Secretagogues: The Only Multi-Year Data

The longest controlled human study in this area is a 2008 trial of MK-677 (ibutamoren). It isn't a peptide itself, but it's an oral ghrelin mimetic that acts on the same receptor as the GHRP-type peptides. In the trial, 65 healthy adults aged 60 to 81 received 25 mg a day or placebo for up to two years. GH and IGF-1 rose into the range of healthy young adults. Fat-free mass rose by about 1.1 kg while it fell slightly on placebo, but strength and function didn't change.

The metabolic costs showed up too. Fasting glucose rose by about 5 mg/dL, insulin sensitivity fell, and cortisol rose. Appetite increased at first and settled over a few months, and mild leg swelling and muscle pain were the other common complaints. The authors reported that the two-year analyses matched the one-year results.

The participants were older adults, not people training hard, and the authors note the study was too small to judge function. What it does show is that GH stimulation can be kept up for years in people, and that the glucose and cortisol effects don't fade.

The other long MK-677 trial is a warning. In a Phase IIb trial of 123 older adults recovering from hip fracture, 25 mg a day raised IGF-1 but didn't improve most measures of physical function, and the trial was stopped early over a congestive heart failure signal. As of October 2026, FDA cites that trial when listing ibutamoren in Category 2 of its compounding lists, the group of substances that may present significant safety risks. Whether the signal applies to healthy, younger users is unknown.

Tolerance is the other long-term question. In a 16-week study of twice-daily hexarelin injections in 12 healthy older adults, the GH response to a dose fell to a little over half of its starting level by week 16. Four weeks after stopping, a test dose produced the same response as at the start. That small study is the main human evidence behind the on/off schedules users describe for GH secretagogues, which our page on cycling strategies for recovery peptides covers.

BPC-157 and TB-500: No Long-Term Data

BPC-157's evidence is emerging: consistent animal data and very little in people. A 2025 systematic review in HSS Journal found 36 eligible studies, 35 of them preclinical. In rats and dogs, repeated dosing for up to 6 weeks caused no tissue changes in the organs examined. No study looked at adverse events beyond 6 weeks, and the review, which searched the literature through June 2024, found no human safety studies.

The human data since then are thin. A 2025 pilot gave 2 adults an IV infusion of 10 mg and then 20 mg of BPC-157 on consecutive days and found no changes in the blood markers tested. In the one retrospective human study the review included, 7 of 12 people with chronic knee pain reported relief lasting more than six months after a knee injection. That is the longest follow-up of any BPC-157 outcome in people, but it had no control group and measured pain, not tissue.

TB-500's evidence is preliminary. It's a 7-amino-acid fragment of thymosin beta-4, and as of October 2026 FDA says it has not identified any human exposure data for the fragment.

Two theoretical concerns come up often:

• Angiogenesis. In lab studies BPC-157 raises VEGF and related signals, which is the proposed basis of its tendon effects. A 2025 narrative review notes that pathologic angiogenesis is involved in tumor growth, so sustained pro-angiogenic signaling is a fair concern. The same review says the effects seem to depend on tissue context: in animals it supported corneal healing without new blood vessel growth, and other preclinical work found it suppressed VEGF-driven tumor growth. Neither direction has been tested in people over long periods.
• Immune reactions. FDA's compounding review lists a possible risk of immunogenicity (the immune system reacting to the peptide or its impurities) for BPC-157, TB-500 and several GH-releasing peptides, partly because peptides can clump and carry impurities. Repeated courses mean repeated exposure. The 2025 systematic review also lists unregulated manufacturing and contamination among the possible sources of harm.

Effects on Natural Healing

A common worry is that relying on peptides for every injury might weaken the body's own repair over time. We found no study in animals or people that tested this. The opposite claim, that years of use leave tissue stronger, is just as untested.

Tissue biology puts some limits on both claims. A 2013 study used carbon-14 from 1950s and 1960s nuclear bomb tests to date tissue in 28 human Achilles tendon samples. The tendon core carried carbon levels from roughly the donors' first 17 years of life, which means it is essentially not renewed in adulthood. Skeletal muscle samples, by contrast, showed continuous turnover. Injured tendon does heal with new tissue, which is where the animal studies focus, but claims about better baseline tendon quality after years of use run against how little adult tendon renews.

What Users Report Over Longer Periods

Forum threads describe usage patterns more than outcomes. Many users describe repeated short BPC-157 courses, alone or with TB-500, each time an injury flares. Some describe running GH secretagogues for months at a time during training blocks, and water retention and stronger hunger come up often in those reports, which fits the MK-677 trial data.

Long-term BPC-157 and TB-500 users mostly report no obvious problems, but those are self-selected posts from people who kept using the peptides. Nobody tracks the users who stopped, or problems people didn't connect to a peptide taken years earlier. For recovery methods with longer track records, see our comparison of peptides with other recovery methods. Years of use also raise sport-rule and fairness questions for tested athletes, covered in the ethics of using peptides for recovery.

What We Still Don't Know

• Whether any recovery peptide changes injury rates or tissue quality over years in people.
• Whether BPC-157 is safe beyond 6 weeks in any species.
• Whether the heart failure and glucose signals seen with MK-677 apply to healthy, younger lifters.
• Whether repeated injection of gray-market peptides leads to immune reactions over time.

What to Watch Next

As of October 2026, the University of Arkansas has registered the first randomized, placebo-controlled BPC-157 trial (NCT07803250). It plans daily subcutaneous injections of BPC-157 or saline for 90 days after rotator cuff surgery, with shoulder strength measured at 12 weeks and 5 months, and it is listed to start in January 2027. Even when it reads out, 90 days of dosing in surgical patients won't settle what years of use do.